Skip to main content

Table 1 Patient characteristics

From: Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

Population (N = 54)
  Median [range]
Age 65 [41–87]
  N %
Sex
 Men 42 77.8
 Women 12 22.2
ECOG
 0 20 37.0
 1 25 46.3
 2 8 14.8
 3 1 1.9
Stage of the tumor at diagnosis
 0 3 5.6
 1 15 27.7
 2 13 24.1
 3 7 13.0
 4 16 29.6
Primary Location
 Upper Urinary Tract 3 5.6
 Bladder 51 94.4
Type of predominant cells
 transitional cell carcinoma 31 57.4
 Other 14 25.9
 Not available 9 16.7
Type of cancer at time of enrollment
 Metastatic 44 81.5
 Locally advanced 10 18.5
Sites of metastasis (could be more than one)
 Lung 20 37.0
 Pleura 1 1.9
 Liver 21 38.9
 Bones 22 40.7
 Brain 2 3.7
 Nodes 27 50
 Other 11 20.4
Neoadjuvant Chemotherapy
 Yes 6 11.1
 No 48 88.9
Adjuvant Chemotherapy
 Yes 13 24.1
 No 41 75.9